Mario L Marques-Piubelli, Riyad N H Seervai, Kumaran M Mudaliar, Wencai Ma, Denái R Milton, Jing Wang, Aaron Muhlbauer, Edwin R Parra, Luisa M Solis, Priyadharsini Nagarajan, Jodi Speiser, Courtney Hudgens, Woo Cheal Cho, Phyu P Aung, Anisha Patel, Omar Pacha, Kelly C Nelson, Michael T Tetzlaff, Rodabe N Amaria, Carlos A Torres-Cabala, Victor G Prieto, Ignacio I Wistuba, Jonathan L Curry
BACKGROUND: Immune checkpoint inhibitor (ICI)-based cancer therapies cause a variety of cutaneous immune-related adverse events (irAEs) including immunobullous skin eruptions like bullous pemphigoid (BP). However, little is known about the underlying immunopathogenic drivers of these reactions, and understanding the unique gene expression profile and immune composition of BP-irAE remains a critical knowledge gap in the field of oncodermatology/oncodermatopathology. METHODS: BP-irAE (n = 8) and de novo BP control (n = 8) biopsy samples were subjected to gene expression profiling using the NanoString® Technologies nCounter PanCancer Immune Profiling Panel...
May 7, 2023: Journal of Cutaneous Pathology